LIB-01: Risks & Legal Status
Important safety information, risks, and regulatory status
📌TL;DR
- •4 risk categories identified
- •0 high-severity risks
- •Legal status varies by country (4 countries listed)
Risk Assessment
LIB-01 is an investigational compound in Phase 2 clinical trials. It has not undergone full regulatory review and the complete safety profile is unknown. All efficacy and safety data are from limited early-phase studies.
Safety data are available from approximately 200 subjects across Phase 1 and Phase 2a studies. Long-term safety, effects of repeated dosing courses, and rare adverse events cannot be assessed from this limited exposure.
MC4R modulation may carry risks including blood pressure changes, nausea, and potential effects on appetite and metabolism. Bremelanotide, which acts on the same pathway, carries a black box-equivalent warning about transient blood pressure increases.
Effects on fertility, pregnancy, and fetal development have not been published. Given the central nervous system mechanism of action, potential effects on reproductive hormones and fertility require evaluation.
⚠️Important Warnings
- •LIB-01 is an investigational compound available ONLY through regulated clinical trials. It is not approved for sale, prescription, or self-administration in any jurisdiction.
- •Do not attempt to obtain or self-administer LIB-01 or plant-derived libiguin preparations. Natural Neobeguea mahafalensis extracts contain variable and unpredictable concentrations of active compounds.
- •The melanocortin-4 receptor pathway is involved in cardiovascular regulation, appetite control, and multiple other physiological functions. MC4R-modulating compounds may have systemic effects beyond sexual function.
- •Long-term effects of MC4R pathway modulation are unknown. Chronic upregulation of melanocortin signaling could theoretically affect body weight regulation, blood pressure, or other melanocortin-mediated processes.
Legal Status by Country
| Country | Status | Notes |
|---|---|---|
| United States | Investigational | LIB-01 is an investigational drug not approved by the FDA. Available only through clinical trials. Not scheduled as a controlled substance. |
| European Union | Investigational | Clinical trials conducted in Sweden, Denmark, and the Netherlands under EU Clinical Trials Regulation. Not approved by EMA. |
| United Kingdom | Investigational | Not approved by MHRA. No clinical trial activity reported in the UK. |
| Australia | Investigational | Not approved by TGA. Not available commercially or through clinical trials in Australia. |
Community Risk Discussions
See how the community discusses and manages these risks in practice.
0View community protocolsCritical Safety Information#
LIB-01 is an investigational compound developed by Dicot Pharma that is currently in Phase 2 clinical trials. It has not been approved by any regulatory authority for any indication. All information below is based on limited clinical trial data and should not be interpreted as a safety profile sufficient for clinical use outside of regulated trials.
Risk Categories#
Investigational Status Risk#
The most fundamental risk of LIB-01 is that it remains investigational. Phase 2 data from approximately 200 subjects cannot characterize uncommon or rare adverse events, long-term safety, or interactions with the full range of concomitant medications and comorbidities seen in clinical practice. The history of drug development demonstrates that many compounds with favorable Phase 2 profiles encounter safety signals in larger Phase 3 trials or post-marketing surveillance.
Melanocortin Pathway Risks#
LIB-01 modulates the melanocortin-4 receptor, a pathway with diverse physiological roles:
- Cardiovascular regulation: MC4R signaling influences blood pressure and heart rate through sympathetic nervous system modulation. Bremelanotide, a direct MC4R agonist, is associated with transient blood pressure increases and carries a warning against use in patients with uncontrolled hypertension or cardiovascular disease
- Energy homeostasis: MC4R is a critical regulator of appetite and energy balance. Gain-of-function MC4R mutations cause lean phenotypes while loss-of-function mutations cause severe obesity. Chronic MC4R pathway modulation could theoretically affect body weight
- Mood and behavior: MC4R is expressed in brain regions involved in stress response and mood regulation. The behavioral implications of long-term MC4R pathway modulation are unknown
Long-Duration Effect Risk#
LIB-01's sustained 4-8 week pharmacodynamic effect is both its therapeutic advantage and a potential safety concern. Unlike drugs with short half-lives where adverse effects resolve quickly upon discontinuation, any adverse effects from LIB-01 could theoretically persist for weeks after the 3-day dosing course. There is no known reversal agent.
Natural Product Derivative Risks#
LIB-01 is derived from a plant used in traditional medicine. While the pharmaceutical product undergoes rigorous quality control, attempts to use raw plant material (Neobeguea mahafalensis root bark) would carry significant risks:
- Variable and unpredictable active compound concentrations
- Presence of other potentially toxic limonoids
- No quality control or purity assurance
- Dosing precision impossible with crude plant material
Regulatory and Legal Status#
LIB-01 is an investigational compound with no regulatory approval in any jurisdiction. It is not a controlled substance, but it is also not legally available for purchase or self-administration outside of regulated clinical trials conducted by Dicot Pharma.
| Jurisdiction | Status | Clinical Trials |
|---|---|---|
| United States | Investigational | No US trials reported |
| Sweden | Investigational | Phase 2a trial sites |
| Denmark | Investigational | Phase 2a trial sites |
| Netherlands | Investigational | Phase 2a trial sites |
| European Union | Investigational | Under EU CTR |
At-Risk Populations#
Cardiovascular Disease#
Patients with uncontrolled hypertension or established cardiovascular disease should be considered at elevated risk given the melanocortin pathway's role in cardiovascular regulation. This concern is reinforced by the bremelanotide precedent, where transient blood pressure increases led to specific cardiovascular warnings.
Psychiatric Conditions#
The central nervous system mechanism of LIB-01 suggests caution in patients with mood disorders or psychiatric conditions until more data are available on CNS effects.
Women and Children#
LIB-01 has been studied exclusively in adult males. No data exist on safety in women, children, or adolescents. Reproductive toxicology data have not been published.
Risk Mitigation#
As an investigational compound, the primary risk mitigation is that LIB-01 is available only through regulated clinical trials with appropriate:
- Informed consent procedures
- Medical screening and eligibility criteria
- Adverse event monitoring
- Ethics committee oversight
- Regulatory authority supervision (via EU Clinical Trials Regulation)
Related Reading#
Frequently Asked Questions About LIB-01
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.